Bilateral effect following off label unilateral intravitreal brolucizumab injection in patient with pseudophakic cystoid macular edema

Abstract

Purpose

To report a bilateral reduction in pseudophakic cystoid macular edema (PCME) after unilateral intravitreal injection (IVI) of brolucizumab.

Observations

A 64-year-old female with bilateral recalcitrant PCME was treated with one dose of intravitreal ozurdex implant and triamcinolone acetonide each in both the eyes, with an equivocal response. On switching to IVI brolucizumab in the right eye (OD), the patient showed significant improvement in the best-corrected visual acuity (BCVA) with a notable reduction in the intraretinal fluid (IRF) and central subfield thickness (CST) in both the eyes at one month.

Conclusions and Importance

In conclusion, IVI brolucizumab is effective for the management of recalcitrant PCME with good visual and anatomical outcomes at one month. However, this molecule can also have therapeutic efficacy in the uninjected eye possibly due to systemic escape. More research into the pharmacokinetic properties of this novel molecule is needed to validate our findings.

Keywords

brolucizumab pseudophakic cystoid macular edema bilateral effect

Get full access to this article

View all access options for this article.

References

Grzybowski

Sikorski

Ascaso

, et al. Pseudophakic cystoid macular edema: update 2016. Clin Interv Aging 2016; 11: 1221–1229.

Guo

Patel

Baumrind

, et al. Management of pseudophakic cystoid macular edema. Surv Ophthalmol 2015; 60(2): 123–137.

Yorston

. Anti-VEGF drugs in the prevention of blindness. Community Eye Health 2014; 27(87): 44–46.

Donati

Lindsley

, et al. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2020; 5(5): CD012208. Published 2020 May 5. doi:10.1002/14651858.CD012208.pub2.

Campa

Alivernini

Bolletta

, et al. Anti-VEGF therapy for retinal vein occlusions. Curr Drug Targets 2016; 17(3): 328–336.

Mansour

Browning

Wong

, et al. The evolving treatment of diabetic retinopathy. Clin Ophthalmol 2020; 14: 653–678.

Chakraborty

Sheth

Boral

, et al. Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: a real-world case series. Am J Ophthalmol Case Rep 2021; 24: 101197.

Al-Dhibi

Khan

. Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema. J AAPOS 2009; 13: 400–402.

Sadda

. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report. Ann Acad Med Singapore 2008; 37: 591–359.

10.

Jonas

Harder

Kamppeter

. Inter-Eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2008; 145: 854–861.

11.

Sharma

Sheth

Madhusudan

, et al. Effect of intravitreal dexamethasone implant on the contralateral eye: a case report. Retin Cases Brief Rep 2013; 7(3): 217–219.

12.

Campos Polo

Rubio Sánchez

. Anti-VEGF and its impact on the outer retina: retinal pigment epithelium tear after an injection of aflibercept in contralateral eye. Arch Soc EspOftalmol 2016; 91(5): 245–249.

13.

Yonekawa

Kim

. Pseudophakic cystoid macular edema. CurrOpin Ophthalmol 2012; 23(1): 26–32.

14.

Arevalo

Maia

Garcia-Amaris

, et al. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the pan-American collaborative retina study group results. Ophthalmology 2009; 116(8): 1481–1487.e1.

15.

Demirel

Batioğlu

Özmert

. Intravitreal ranibizumab for the treatment of cystoid macular edema in Irvine-Gass syndrome. J OculPharmacolTher 2012; 28(6): 636–639.

16.

Lin

Tsai

. Use of aflibercept for the management of refractory pseudophakic macular edema in Irvine-Gass syndrome and literature review. Retin Cases Brief Rep 2018; 12(1): 59–62.

17.

Avery

Castellarin

Steinle

, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 2014; 98(12): 1636–1641.